Mitrassist Lifesciences Limited

Founded in 2017, Mitrassist Lifesciences Limited is a globally leading, innovation-driven platform medical device company in the cardiovascular field. Mitrassist focuses on multiple major cardiovascular segments, including structural heart disease, heart failure, and coronary interventions, and has built a comprehensive and diversified product pipeline. The company holds over 100 authorized PCT patents worldwide. R&D centers have been established in China, Israel, and Germany, while independent sales teams operate in China and the United States. Currently, Mitrassist has developed a mature distributor network covering more than 20 countries and regions across Europe, Asia, and the Americas.

The founding team of Mitrassist consists of seasoned professionals with many years of experience in the medical device industry, combining disruptive technological innovation capabilities with a strong global vision. Since its establishment, the company has completed multiple consecutive financing rounds from top-tier investment institutions.

Mitrassist’s headquarters integrates full-cycle capabilities, including R&D, testing, manufacturing, clinical operations, regulatory affairs, academic promotion, marketing, and strategic integration. The management team brings extensive leadership experience in the cardiovascular medical device sector. The company currently employs over 300 staff members, including numerous PhD and Master’s degree holders. Both the management team and the R&D and sales teams average more than 15 years of experience in the cardiovascular field.

Mitrassist is equipped with high-precision, highly automated manufacturing and testing equipment, as well as state-of-the-art laboratories. The company operates cleanroom facilities compliant with national standards for Class III implantable medical device manufacturing.

Since its founding, Mitrassist has committed to promoting the accessibility and inclusiveness of cardiovascular diagnosis and treatment. The company continuously pursues technological breakthroughs under the philosophy of “superior where others exist, pioneering where none exist.”

On July 6, 2022, the world’s first polymer transcatheter aortic valve replacement (Polymer TAVR) product, SIKELIA®, independently developed by Mitrassist, was successfully implanted for the first time globally by Professor Ge Junbo’s team at Zhongshan Hospital, Fudan University. This milestone marks the entry of interventional valve therapy into the polymer era, with the potential to significantly extend valve durability, improve manufacturing consistency, and reduce costs, thereby demonstrating China’s global leadership in cardiovascular medical device innovation. This project was awarded the “Winner Award” in the medical device category of the 2022 National Disruptive Technology Innovation Competition organized by China’s Ministry of Science and Technology.

Mitrassist’s independently developed Mitrafix®, China’s first transapical transcatheter mitral valve replacement system, has entered the National Medical Products Administration’s Special Review Program for Innovative Medical Devices. The product requires only ultrasound guidance, offering the advantages of high safety, ease of use, and strong scalability.

The company’s non-invasive heart failure management device, ReDS™ Pro Non-Invasive Lung Fluid Measurement System, has been approved and launched in the United States, Europe, India, and Japan, and received approval in China in April 2023. ReDS™ is currently the world’s only non-invasive heart failure management device based on the “5A” principle.

In the coronary field, Mitrassist’s product Smartbird® Drug-Coated Coronary Balloon Catheter has been approved for marketing in China. It is the first domestically approved product utilizing fourth-generation paclitaxel drug-coating technology.